rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2409-2231-2015-2-2-35-43rpmj-61Research ArticleОбзорыReviewПроблемы диагностики и лечения первично операбельного рака молочной железыProblems of diagnosis and treatment of primary operable breast cancerТрошенковЕ. А.TroshenkovE. A.

к.м.н., ведущий хирург отделения общей онкологии МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России

PhD, leading surgeon of department of general oncology of  P. Hertsen MORI 

7783949@mail.ruКостинА. А.KostinA. A.

д.м.н., профессор, первый заместитель генерального директор ФГБУ «НМИРЦ» Минздрава России, заведующий кафедрой урологии, онкологии и радиологии ФПК МР РУДН

MD., professor, vice director of  NMRRC

МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России 125284, Российская Федерация, г. Москва, 2-ой Боткинский проезд, дом 3РоссияP. Hertsen MORI 2-y Botkinskiy proezd, 3, 125284, Moskva, 125284, RussiaRussian FederationФГБУ «НМИРЦ» Минздрава России 249036, Российская Федерация, Калужская область, г. Обнинск, ул. Королёва, д. 4РоссияNMRRC Ulitsa Korolyeva, d. 4, Oblinsk, Kaluzskaya Oblast’, 249036, RussiaRussian Federation201511062015223543Copyright © Трошенков Е.А., Костин А.А., 20152015Трошенков Е.А., Костин А.А.Troshenkov E.A., Kostin A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/61

Рак молочный железы - гетерогенное заболевание, обладающее генотипической и фенотипической вариабельностью. Фенотипическое разнообразие опухолей напрямую связано с генотипическими вариациями, которые можно определить с помощью анализа экспрессии генов при комплексном иммуногистохимическом исследовании. На сегодняшний день существует великое множество методик хирургического лечения – от малоинвазивных до радикальных-, вариабельных по количеству этапов, наличия и объема реконструктивных приемов. На передний план выходят органосохраняющие операции.

Cancer breast cancer is a heterogeneous disease with genotypic and phenotypic variability. Phenotypic diversity of tumors is directly related to genotypic variations, which can be determined with analyzing gene expression in a comprehensive immunohistochemical study. Today there are many methods of surgical treatment – from minimally invasive to radical, variable according to the number of stages, the volume of reconstructive techniques. Today organ-preserving operations are prefered by surgeons all the world.

первично операбельный рак молочной железыиммуногистохимияорагносохраняющие операциикомплексная терапиякомбинированное лечениеfirst operable cancer breastimmunohystiochemistryreconstructionorgan-preserving operationscomplex therapyReferencesGoldhirsch A., Winer E.P., Coates A.S., Gelber R.D. Panel members† Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology. 2013; 24.(9): 2206-2223.Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D. Panel members† Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology. 2013; 24.(9): 2206-2223.Park S., Koo J., Park H.S., et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;.21: 488–492.Park S., Koo J., Park H.S., et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;.21: 488–492.Park S., Park H.S., Kim S.I. The impact of a focally positive resection margin on the local control in patients treated with breast-conserving therapy. J Clin Oncol.2011; 5:.600-608.Park S., Park H.S., Kim S.I. The impact of a focally positive resection margin on the local control in patients treated with breast-conserving therapy. J Clin Oncol.2011; 5:.600-608.Gobardhan P.D., de Wall L.L., van der Laan L., ten Tije A.J. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013; 24(3): 668-673.Gobardhan P.D., de Wall L.L., van der Laan L., ten Tije A.J. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013; 24(3): 668-673.Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2010; 5: 5–23.Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2010; 5: 5–23.Cancello G. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Annals of Oncology. 2013; 24: 661–668Cancello G. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Annals of Oncology. 2013; 24: 661–668Oh D.S., Troester M.A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006; 24: 1656–1664.Oh D.S., Troester M.A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006; 24: 1656–1664.Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11: 5678–5685.Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11: 5678–5685.Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 8418–8423.Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 8418–8423.Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009; 69: 4116–4124.Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009; 69: 4116–4124.Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12: R68.Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12: R68.Marcom P.K., Isaacs C., Harris L., et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007; 102: 43–49.Marcom P.K., Isaacs C., Harris L., et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007; 102: 43–49.Cui X., Schiff R., Arpino G., et al.. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;.23: 7721–7735.Cui X., Schiff R., Arpino G., et al.. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;.23: 7721–7735.Rakha E.A., El-Sayed M.E., Green A.R., et al.. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007; 25: 4772–4778.Rakha E.A., El-Sayed M.E., Green A.R., et al.. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007; 25: 4772–4778.Creighton C.J., Kent Osborne C., van de Vijver M.J., et al.. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009; 114: 287–299.Creighton C.J., Kent Osborne C., van de Vijver M.J., et al.. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009; 114: 287–299.Cuzick J., Dowsett M., Pineda S., et al.. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011; 29: 4273–4278.Cuzick J., Dowsett M., Pineda S., et al.. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011; 29: 4273–4278.Hugh J., Hanson J., Cheang M.C., et al.. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an Immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol. 2009; 27: 1168–1176.Hugh J., Hanson J., Cheang M.C., et al.. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an Immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol. 2009; 27: 1168–1176.Cheang M.C., Chia S.K., Voduc D., et al. Ki67 Index, HER2 Status, and prognosis of patients with luminal B breast Cancer. J Natl Cancer Inst. 2009; 101: 736–750.Cheang M.C., Chia S.K., Voduc D., et al. Ki67 Index, HER2 Status, and prognosis of patients with luminal B breast Cancer. J Natl Cancer Inst. 2009; 101: 736–750.Gayathri Nagaraj, Ma C.X. Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor–Positive, HER2-Negative Breast Cancer: Challenges and Considerations . JNCCN. 2013; 11(3): 246-251.Gayathri Nagaraj, Ma C.X. Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor–Positive, HER2-Negative Breast Cancer: Challenges and Considerations . JNCCN. 2013; 11(3): 246-251.Волченко А.А., Чиссов В.И., Зикиряходжаев А.Д. Выбор реконструктивно-пластических операций при комплексном лечении больных раком молочной железы. Онкология. Журнал им. П.А. Герцена. 2014; № 1: 3-9.Волченко А.А., Чиссов В.И., Зикиряходжаев А.Д. Выбор реконструктивно-пластических операций при комплексном лечении больных раком молочной железы. Онкология. Журнал им. П.А. Герцена. 2014; № 1: 3-9.Bleyer A., Welch H.W. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. N Engl J Med. 2012; 367: 1998- 2005.Bleyer A., Welch H.W. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. N Engl J Med. 2012; 367: 1998- 2005.Besluit van 16 juli 2001, houdende vaststelling van het besluit stralingsbescherming.12. 2. URL: http://www.sbng.nl (accessed 20.04.2015).Besluit van 16 juli 2001, houdende vaststelling van het besluit stralingsbescherming.12. 2. URL: http://www.sbng.nl (accessed 20.04.2015).Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.Cianfrocca M., Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004; 9: 606–616.Cianfrocca M., Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004; 9: 606–616.Dowsett M., Lopez-Knowles E., Sidhu K., et al. Comparison of PAM50 risk of recurrence (ROR) score with Oncotype DX and IHC4 for predicting residual risk of RFS and distant-(D)RFS after endocrine therapy: a transATAC study. Cancer Res. 2011; 71(3): 4–5.Dowsett M., Lopez-Knowles E., Sidhu K., et al. Comparison of PAM50 risk of recurrence (ROR) score with Oncotype DX and IHC4 for predicting residual risk of RFS and distant-(D)RFS after endocrine therapy: a transATAC study. Cancer Res. 2011; 71(3): 4–5.Dabbs D.J., Klein M.E., Mohsin S.K., et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol. 2011; 29: 4279–4285.Dabbs D.J., Klein M.E., Mohsin S.K., et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol. 2011; 29: 4279–4285.Baehner F.L., Achacoso N., Maddala T., et al. Human epidermal growth factor receptor 2 assessment in a case–control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010; 28: 4300–4306.Baehner F.L., Achacoso N., Maddala T., et al. Human epidermal growth factor receptor 2 assessment in a case–control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010; 28: 4300–4306.Hammond M.E., Hayes D.F., Dowsett M. et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16): 2784–2795.Hammond M.E., Hayes D.F., Dowsett M. et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16): 2784–2795.Hammond M.E., Hayes D.F., Wolff A.C. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011; 29: e458.Hammond M.E., Hayes D.F., Wolff A.C. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011; 29: e458.Vaz-Luis I., Winer E.P., Lin N. U. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Annals of Oncology. 2013;.24: 283–291.Vaz-Luis I., Winer E.P., Lin N. U. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Annals of Oncology. 2013;.24: 283–291.Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3726–3734.Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3726–3734.Carlson R.W., Allred D.C., Anderson B.O., et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3, 2012. URL: www.nccn.org (accessed 17.01.2013).Carlson R.W., Allred D.C., Anderson B.O., et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3, 2012. URL: www.nccn.org (accessed 17.01.2013).Mook S., Schmidt M.K., Rutgers E.J., et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009; 10: 1070–1076.Mook S., Schmidt M.K., Rutgers E.J., et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009; 10: 1070–1076.Caruso F., Ferrara M., Castiglione G., Trombetta G., De Meo L., Catanuto G., Carillio G. Nipple sparing subcutaneous mastectomy: sixty-six months follow-up. Eur J Surg Oncol.2006; 32(9): Р.937.Caruso F., Ferrara M., Castiglione G., Trombetta G., De Meo L., Catanuto G., Carillio G. Nipple sparing subcutaneous mastectomy: sixty-six months follow-up. Eur J Surg Oncol.2006; 32(9): Р.937.Sacchini V.S., de Alcantara Filho P., Capko D., Barry J.M., Morrow M. Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol. 2011; 18(11): 3117-22.Sacchini V.S., de Alcantara Filho P., Capko D., Barry J.M., Morrow M. Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol. 2011; 18(11): 3117-22.Komorowski A.L., Zanini V., Regolo L., Carolei A., Wysocki W.M., Costa A. Necrotic complications after nipple- and areola-sparing mastectomy.World J Surg. 2006; 30(8): 1410.Komorowski A.L., Zanini V., Regolo L., Carolei A., Wysocki W.M., Costa A. Necrotic complications after nipple- and areola-sparing mastectomy.World J Surg. 2006; 30(8): 1410.Galimberti V., Cole B.F., Zurrida S.. et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14: 297–305.Galimberti V., Cole B.F., Zurrida S.. et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14: 297–305.Giuliano A.E., Hunt K.K., Ballman K.V.. et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569–575.Giuliano A.E., Hunt K.K., Ballman K.V.. et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569–575.Voogd A.C., van Oost F.J., Rutgers E.J., et al. Long term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J cancer. 2005; 41: 2637-2644.Voogd A.C., van Oost F.J., Rutgers E.J., et al. Long term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J cancer. 2005; 41: 2637-2644.Hughes J.H., Mason M.C., Gray R.J., et al. A Multi-site validation trial of radioactive seed localization as an alternative to wire localization. Breast J. 2008; 14: 153-157.Hughes J.H., Mason M.C., Gray R.J., et al. A Multi-site validation trial of radioactive seed localization as an alternative to wire localization. Breast J. 2008; 14: 153-157.Lovrics P.J., Goldsmith C.H., Hodgson N., et al. A multicentered, randomized, controlled trial comparing radio guided seed localization to standard wire localization for nonpalpable invasive and in situ breast carcinomas. Ann Surg Oncol. 2011; 18: 3407-3414.Lovrics P.J., Goldsmith C.H., Hodgson N., et al. A multicentered, randomized, controlled trial comparing radio guided seed localization to standard wire localization for nonpalpable invasive and in situ breast carcinomas. Ann Surg Oncol. 2011; 18: 3407-3414.Centraal BegeleidingsOrgaan (CBO). Fysieke en cognitieve effecten, voorlichting en psychosociale zorg. In: Richtlijn mammacarcinoom 2008. P. 222-224.Centraal BegeleidingsOrgaan (CBO). Fysieke en cognitieve effecten, voorlichting en psychosociale zorg. In: Richtlijn mammacarcinoom 2008. P. 222-224.Krekel N.M., Zonderhuis B.M., Scheurs H.W.H., et al. Ultrasound-guided breast-sparing surgery to improve cosmetic outcomes and quality of life. A prospective multicentre randomized controlled clinical trial comparing ultrasound-guided surgery to traditional palpation guided surgery (COBALT trial). BMC Surg. 2011; 16: 11-18.Krekel N.M., Zonderhuis B.M., Scheurs H.W.H., et al. Ultrasound-guided breast-sparing surgery to improve cosmetic outcomes and quality of life. A prospective multicentre randomized controlled clinical trial comparing ultrasound-guided surgery to traditional palpation guided surgery (COBALT trial). BMC Surg. 2011; 16: 11-18.Pleijhuis R.G., Langhout G.C., Helfrich W., et al. Near-infrared fluorescence (NIRF) imaging in breast-conserving surgery: assessing intraoperative techniques in tissue-simulating breast phantoms. Eur J Surg oncol.. 2011;.37: 32-39.Pleijhuis R.G., Langhout G.C., Helfrich W., et al. Near-infrared fluorescence (NIRF) imaging in breast-conserving surgery: assessing intraoperative techniques in tissue-simulating breast phantoms. Eur J Surg oncol.. 2011;.37: 32-39.Espinosa-Bravo M., Sao Aviles A., Esqueva A., et al. Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods. Eur J Surg Oncol. 2011; 37: 1038-1043.Espinosa-Bravo M., Sao Aviles A., Esqueva A., et al. Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods. Eur J Surg Oncol. 2011; 37: 1038-1043.Krekel N.M., Zonderhuis B.M., Stockmann H.B., et al. A comparison of three methods for nonpalpable breast cancer excision. Eur J Surg Oncol. 2011; 37: 109-115.Krekel N.M., Zonderhuis B.M., Stockmann H.B., et al. A comparison of three methods for nonpalpable breast cancer excision. Eur J Surg Oncol. 2011; 37: 109-115.Weissenbacher T.M., Zschage M., Janni W., et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010; 122: 27-34.Weissenbacher T.M., Zschage M., Janni W., et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010; 122: 27-34.Bauman L., Barth R.J., Rosenkranz K.M.. Breast conservation in women with multifocal-multicentric breast cancer: is it feasible? Ann Surg Oncol. 2010; 17: 325-329.Bauman L., Barth R.J., Rosenkranz K.M.. Breast conservation in women with multifocal-multicentric breast cancer: is it feasible? Ann Surg Oncol. 2010; 17: 325-329.Yerushalmi R., Tyldesley S., Woods R., et al. Is breast conserving therapy a safe option for patients with tumor multicentricity and multifocality. Ann Oncol. 2012; 23: 876-881.Yerushalmi R., Tyldesley S., Woods R., et al. Is breast conserving therapy a safe option for patients with tumor multicentricity and multifocality. Ann Oncol. 2012; 23: 876-881.Massarweh S., Osborne C.K., Jiang S., et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006; 66: 8266–8273.Massarweh S., Osborne C.K., Jiang S., et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006; 66: 8266–8273.Guarneri V., Frassoldati A., Bottini A., et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) [abstract]. J Clin Oncol. 2011; 29: a507.Guarneri V., Frassoldati A., Bottini A., et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) [abstract]. J Clin Oncol. 2011; 29: a507.Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet.2012; 379: 633–640.Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet.2012; 379: 633–640.Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96: 926–935.Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96: 926–935.Viale G., Regan M.M., Maiorano E., et al.. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007; 25: 3846–3852.Viale G., Regan M.M., Maiorano E., et al.. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007; 25: 3846–3852.Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365: 1273–1283.Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365: 1273–1283.Perez E.A., Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B- 31. J Clin Oncol. 2011; 29: 3366–3373.Perez E.A., Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B- 31. J Clin Oncol. 2011; 29: 3366–3373.Albain K., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive,oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology. 2010; 11(1): 55–65.Albain K., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive,oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology. 2010; 11(1): 55–65.Hornberger J., Chien R. Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice. In Poster Presented at the St Gallen International Breast Cancer Conference, St Gallen, Switzerland, March. 2011; Abstract: 201.Hornberger J., Chien R. Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice. In Poster Presented at the St Gallen International Breast Cancer Conference, St Gallen, Switzerland, March. 2011; Abstract: 201.

The authors declare that there are no conflicts of interest present.